# The Optimal One-Month Dosing of Lemborexant for Moderate Obstructive Sleep Apnea (OSA) Patients With Low Arousal Threshold

> **NCT07683442** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Chulalongkorn University** · enrollment: 36 (estimated)

## Conditions studied

- OSA - Obstructive Sleep Apnea

## Interventions

- **DRUG:** Lemborexant 5 MG [Dayvigo] Period 1
- **DRUG:** Placebo Period 1
- **DRUG:** Lemborexant 5 MG [Dayvigo] Period 2
- **DRUG:** Placebo Period 2
- **DRUG:** Lemborexant 5 MG [Dayvigo] Period 3
- **DRUG:** Placebo Period 3
- **DRUG:** Lemborexant 10 MG [Dayvigo] Period 1
- **DRUG:** Lemborexant 10 MG [Dayvigo] Period 2
- **DRUG:** Lemborexant 10 MG [Dayvigo] Period 3

## Key facts

- **NCT ID:** NCT07683442
- **Lead sponsor:** Chulalongkorn University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-01
- **Primary completion:** 2028-06-30
- **Final completion:** 2028-06-30
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07683442

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07683442, "The Optimal One-Month Dosing of Lemborexant for Moderate Obstructive Sleep Apnea (OSA) Patients With Low Arousal Threshold". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07683442. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*